Immunotech Biopharm invests RMB120m in structured deposits

Immunotech Biopharm Ltd. has agreed to subscribe for two structured deposit products from Bank of China Limited, totaling RMB120,000,000. On December 8, 2025, the company subscribed to Structured Deposit Product I for RMB20,000,000 and Structured Deposit Product II for RMB100,000,000.

Structured Deposit Product I has a 20-day term, is linked to the EUR/USD spot exchange rate, and offers an annualized return of 0.4000% to 1.5800%. Structured Deposit Product II, with a 62-day term, is linked to the NZD/USD spot exchange rate and provides an annualized return of 0.6000% to 1.9000%.

These transactions are a discloseable transaction for the company under Chapter 14 of the Listing Rules, as one of the applicable percentage ratios exceeds 5% but remains below 25%. Immunotech Biopharm stated these investments are part of its cash management strategy for temporarily idle raised funds, aiming to ensure capital safety and liquidity without affecting the intended use of such funds. The directors consider the terms of these agreements to be fair and reasonable, on normal commercial terms or better.